In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Stratification of symptomatic patients with low to intermediate risk of coronary artery disease

Session Poster session 1

Speaker Simon Winther

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : S Winther (Aarhus,DK), L Nissen (Herning,DK), J Westra (Aarhus,DK), L Frost (Silkeborg,DK), G Urbonaviciene (Silkeborg,DK), NR Holm (Aarhus,DK), EH Christiansen (Aarhus,DK), HE Botker (Aarhus,DK), M Bottcher (Herning,DK)

S. Winther1 , L. Nissen2 , J. Westra1 , L. Frost3 , G. Urbonaviciene3 , N.R. Holm1 , E.H. Christiansen1 , H.E. Botker1 , M. Bottcher2 , 1Aarhus University Hospital, Dept. of Cardiology - Aarhus - Denmark , 2Regional Hospital West Jutland, Dept. of Cardiology - Herning - Denmark , 3Regional Hospital Central Jutland, Dept. of Cardiology - Silkeborg - Denmark ,

On behalf: DAN-NICAD study group

European Heart Journal ( 2017 ) 38 ( Supplement ), 189

Background: Clinical risk stratification of patients with symptoms suggestive of obstructive coronary artery disease (CAD) remains a challenge. The initial diagnostic test often turns out to be normal and requires substantial healthcare resources. However, current primary risk prediction model, Diamond-Forrester score (DF-score), are currently not validated in patients with low/intermediate risk.

Purpose: To investigate the ability of clinical risk factors and DF-score to predict patients with suspected hemodynamically obstructive CAD compared to coronary artery calcium score (CACS).

Methods: We included 1675 consecutive patients (male: 49% mean age 57±8 years) referred to coronary computed tomography angiography (CTA) with symptoms suggestive of CAD and a low-intermediate risk profile. A medical interview was conducted prior to coronary CTA to obtain clinical risk factors. All patients with suspected obstructive CAD by coronary CTA (>50% diameter stenosis) were subsequently investigated by invasive coronary angiography and fractional flow reserve measurements. Hemodynamically obstructive CAD was defined as FFR ≤0.80.

Results: Median DF-score was 0.39 [IQR 0.20–0.53], 83% were at intermediate risk (DF-score 0.15–0.85). A total of 391 (23%) patients had suspected obstructive CAD by coronary CTA and 161 (10%) patients had hemodynamically obstructive CAD verified by invasive coronary angiography. The relative risk ratio of CAD according to single risk factors, symptoms, medication, DF-score and CACS is illustrated in figure. The area under the receiver operating characteristic curve for DF-score was 0.68 (CI: 0.63–0.72), and CACS was 0.86 (CI: 0.83–0.89), p<0.001.

Conclusion: In a cohort of patients with low/intermediate likelihood and symptoms suggestive of CAD, CACS is a very strong predictor of hemodynamically obstructive CAD. Single clinical risk factors and DF-score only show limited capacity for risk stratification.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are